search
Back to results

CARbon Dioxide Flooding to Reduce Postoperative Neurological Injury Following Surgery for Acute Type A Aortic Dissection (CARTA)

Primary Purpose

D000784, D020521

Status
Suspended
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Carbon dioxide flooding
Sponsored by
Region Skane
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for D000784 focused on measuring Aorta, Dissection, Stroke

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Verified acute type A aortic dissection.
  • Patient accepted for surgical repair.

Exclusion Criteria:

  • New-onset neurological symptoms defined as focal neurological symptoms or altered state of consciousness at time of inclusion.
  • History of stroke with permanent neurological deficiency.
  • Previous cardiac surgery.
  • Surgery performed with cross clamping of the aorta without open distal anastomosis or open inspection of the distal aorta.
  • Presence of implants or devices not compatible with Magnetic Resonance Imaging.

Sites / Locations

  • Skane University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Control

Arm Description

Once the thoracic cavity os opened during surgery, carbon dioxide flooding using a diffusor will be instigated with a flow of 5L/min. The flooding will be terminated once the aorta and the heart have no open contact with surrounding air.

No intervention. No sham will be used as the staff performing the surgery would have been able to detect the lack of carbon dioxide in the surgical wound.

Outcomes

Primary Outcome Measures

Number of ischemic lesions on magnetic resonance imaging (MRI)
Number of ischemic lesions visualized using MRI
Size of ischemic lesions on magnetic resonance imaging (MRI)
Size of ischemic lesions visualized using MRI

Secondary Outcome Measures

Clinical neurological injury
Clinical neurological injury (Coma according to clinical neurological assessment and/or clinical focal neurological injuries assessed by neurologist or verified ischemic lesions on MRI).
Neurological function
Patients will be assessed using the National Institute of Health Stroke Scale (NIHSS). Minimum score 0 points, maximum score 42 points, with 42 points being the worst outcome.
Neurological function
Patients will be assessed using the modified Rankin Scale (mRS). Minimum score 0 points, maximum score 6 points, with 6 points being the worst outcome.
Level of consciousness
Patients will be assessed using the Glasgow Coma Scale Motor Score. Minimum score 1 points, maximum score 6 points, with 6 points being the best outcome.
Levels of S100B.
Concentration of S100B at predefined time points.
Levels of NSE.
Concentration of NSE at predefined time points.
Levels of NFL.
Concentration of NFL at predefined time points.
Levels of GFAP.
Concentration of GFAP at predefined time points.
Levels of UCH-L1.
Concentration of UCH-L1 at predefined time points.
Levels of TAU.
Concentration of TAU at predefined time points.
Neurological function after ATAAD surgery.
Patients will be assessed using the National Institute of Health Stroke Scale (NIHSS) three months after surgery. Minimum score 0 points, maximum score 42 points, with 42 points being the worst outcome.
Neurological function after ATAAD surgery.
Patients will be assessed using the modified Rankin Scale (mRS). Minimum score 0 points, maximum score 6 points, with 6 points being the best outcome.
Neurocognitive function after ATAAD surgery.
Patients will be assessed using the Symbol digit modalities test (SDMT). Minimum score 0 points, maximum score 110 points, with 110 points being the best outcome.
Cognitive function after ATAAD surgery.
Patients will be assessed using the Montereal cognitive assesment (MoCA) test. Minimum score 0 points, maximum score 30 points, with 30 points being the best outcome.
Neurological recovery after ATAAD surgery.
Patients will be assessed using the 2 simple questions for stroke). Minimum score 0 points, maximum score 2 points, with 2 points being the worst outcome.
Postoperative recovery after ATAAD surgery.
Patients will be assessed using the Postoperative recovery profile. Minimum score 19 points, maximum score 76 points, with 76 points being the best outcome.
Quality of life after ATAAD surgery.
Patients will be assessed using the Satisfaction with life scale. Minimum score 0 points, maximum score 35 points, with 35 points being the best outcome.
Quality of life after ATAAD surgery.
Patients will be assessed using the EuroQol 5 dimensions 5 levels (EQ-5D-5L). Minimum score 5 points, maximum score 25 points, with 5 points being the best outcome.
Number of ischemic lesions on magnetic resonance imaging (MRI) in relation to the use of retrograde cerebral perfusion.
Number of ischemic lesions visualized using MRI analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Size of ischemic lesions on magnetic resonance imaging (MRI) in relation to the use of retrograde cerebral perfusion.
Size of ischemic lesions visualized using MRI analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Levels of S100B analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Concentration of S100B at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Levels of NSE analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Concentration of NSE at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Levels of NFL analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Concentration of NFL at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Levels of GFAP analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Concentration of GFAP at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Levels of UCH-L1 analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Concentration of UCH-L1 at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Levels of TAU analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Concentration of TAU at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.

Full Information

First Posted
June 9, 2021
Last Updated
August 31, 2023
Sponsor
Region Skane
search

1. Study Identification

Unique Protocol Identification Number
NCT04962646
Brief Title
CARbon Dioxide Flooding to Reduce Postoperative Neurological Injury Following Surgery for Acute Type A Aortic Dissection
Acronym
CARTA
Official Title
CARbon Dioxide Flooding to Reduce Postoperative Neurological Injury Following Surgery for Acute Type A Aortic Dissection - A Prospective, Randomized, Blinded, Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Suspended
Why Stopped
Interim analyses were performed after 40 study participants had been included. Results from the interim analyses raised important questions which need to be assessed by a Data Safety and Monitoring Board. Date of suspension Aug 18th 2023
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Skane

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Aortic dissection is a life-threatening condition and a consequence of a tear of the innermost of the three aortic layers- the intima. When a tear occurs, blood surges through the tear and causes the flow of blood between the aortic layers, causing a "false lumen". This causes a weakening of the aortic wall and hinders the blood from reaching its target organs and life saving emergent surgery is performed as routine. Approximately 20% of patients undergoing acute type a aortic dissection (ATAAD) surgery suffer from postoperative neurological injuries and It has been demonstrated that neurological injuries account for 10-15% of in-hospital deaths. In association with other cardiac procedures where the left side of the heart is opened and air may be trapped within the arterial circulation, carbon dioxide flooding is used to displace open air from the surgical wound. In comparison to air, carbon dioxide is significantly more soluble in blood and may therefore decrease the risk of air embolism. In cardiac surgery, carbon dioxide flooding has been demonstrated to reduce levels of biomarkers of cerebral injury, but carbon dioxide is not routinely employed in ATAAD surgery and has not been studied in association with these procedures. The hypothesis is that carbon dioxide flooding reduces cerebral air embolism and the aim of this project is to evaluate whether carbon dioxide flooding may reduce neurological injuries following ATAAD surgery. This is a prospective, randomized, controlled, patient- and reviewer blinded interventional study. Patients will be randomized to undergo surgery with carbon-dioxide flooding at 5L/min to the open chest cavity or conventional surgery without carbon dioxide flooding. Remaining aspects of the procedure will be identical. The patient, external statistician and the reviewer analyzing the primary endpoints will be blinded for the randomization arms. The study will assess the following endpoints: Primary outcomes: Presence, number and volume of ischaemic lesions observed using magnetic resonance imaging (MRI) after ATAAD surgery. Secondary outcomes: Clinical signs of neurological injury. Levels of biomarkers of neurological injury (S100B, neuron specific enolase (NSE) , neurofilament protein (NFL), Glial fibrillary acid protein (GFAP) , Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) and Tau-protein (TAU)) before and after surgery. Quality of life, postoperative recovery and neurological function after ATAAD surgery. Primary outcomes in relation to retrograde cerebral perfusion. Start of inclusion is anticipated to start Jan 1st, 2022. The writing of a manuscript describing the study methods and study objectives is expected to be started in 2021 and the final manuscript is expected to be written during 2025. An interim analysis of the primary endpoints and the safety arm will be performed after 40 patients have been randomized. An external statistician together with the principle investigator will hereafter decide for the study to be continued or terminated due to harms, futility or superiority. The safety arm will include intraoperative mortality, in-hospital mortality, re-operation for bleeding, stroke, myocardial infarction or other thromboembolic events. Update August 2023: Interim analyses were performed after 40 study participants had been included. Results from the interim analyses raised important questions which need to be assessed by a Data Safety and Monitoring Board (DSMB). Since there are no documented harmful effects of the intervention, a DSMB was not appointed before initiation of the trial. The study was suspended on Aug 18th 2023. A DSMB will be appointed, analyze the interim analyses, collect necessary additional information and make a recommendation to the PI whether the study is may proceed or is to be terminated prematurely.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
D000784, D020521
Keywords
Aorta, Dissection, Stroke

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, randomized, controlled, patient- and reviewer blinded interventional study.
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Once the thoracic cavity os opened during surgery, carbon dioxide flooding using a diffusor will be instigated with a flow of 5L/min. The flooding will be terminated once the aorta and the heart have no open contact with surrounding air.
Arm Title
Control
Arm Type
No Intervention
Arm Description
No intervention. No sham will be used as the staff performing the surgery would have been able to detect the lack of carbon dioxide in the surgical wound.
Intervention Type
Procedure
Intervention Name(s)
Carbon dioxide flooding
Intervention Description
Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
Primary Outcome Measure Information:
Title
Number of ischemic lesions on magnetic resonance imaging (MRI)
Description
Number of ischemic lesions visualized using MRI
Time Frame
MRI will be performed before postoperative day 7. When not possible due to medical considerations, MRI may be performed up to 30 days after surgery.
Title
Size of ischemic lesions on magnetic resonance imaging (MRI)
Description
Size of ischemic lesions visualized using MRI
Time Frame
MRI will be performed before postoperative day 7. When not possible due to medical considerations, MRI may be performed up to 30 days after surgery.
Secondary Outcome Measure Information:
Title
Clinical neurological injury
Description
Clinical neurological injury (Coma according to clinical neurological assessment and/or clinical focal neurological injuries assessed by neurologist or verified ischemic lesions on MRI).
Time Frame
Up to postoperative day 7.
Title
Neurological function
Description
Patients will be assessed using the National Institute of Health Stroke Scale (NIHSS). Minimum score 0 points, maximum score 42 points, with 42 points being the worst outcome.
Time Frame
Postoperative day 4 or at discharge from the ICU.
Title
Neurological function
Description
Patients will be assessed using the modified Rankin Scale (mRS). Minimum score 0 points, maximum score 6 points, with 6 points being the worst outcome.
Time Frame
Postoperative day 4 or at discharge from the ICU.
Title
Level of consciousness
Description
Patients will be assessed using the Glasgow Coma Scale Motor Score. Minimum score 1 points, maximum score 6 points, with 6 points being the best outcome.
Time Frame
Postoperative day 4 or at discharge from the ICU.
Title
Levels of S100B.
Description
Concentration of S100B at predefined time points.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of NSE.
Description
Concentration of NSE at predefined time points.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of NFL.
Description
Concentration of NFL at predefined time points.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of GFAP.
Description
Concentration of GFAP at predefined time points.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of UCH-L1.
Description
Concentration of UCH-L1 at predefined time points.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of TAU.
Description
Concentration of TAU at predefined time points.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Neurological function after ATAAD surgery.
Description
Patients will be assessed using the National Institute of Health Stroke Scale (NIHSS) three months after surgery. Minimum score 0 points, maximum score 42 points, with 42 points being the worst outcome.
Time Frame
3 months after surgery.
Title
Neurological function after ATAAD surgery.
Description
Patients will be assessed using the modified Rankin Scale (mRS). Minimum score 0 points, maximum score 6 points, with 6 points being the best outcome.
Time Frame
3 months after surgery.
Title
Neurocognitive function after ATAAD surgery.
Description
Patients will be assessed using the Symbol digit modalities test (SDMT). Minimum score 0 points, maximum score 110 points, with 110 points being the best outcome.
Time Frame
3 months after surgery.
Title
Cognitive function after ATAAD surgery.
Description
Patients will be assessed using the Montereal cognitive assesment (MoCA) test. Minimum score 0 points, maximum score 30 points, with 30 points being the best outcome.
Time Frame
3 months after surgery.
Title
Neurological recovery after ATAAD surgery.
Description
Patients will be assessed using the 2 simple questions for stroke). Minimum score 0 points, maximum score 2 points, with 2 points being the worst outcome.
Time Frame
3 months after surgery.
Title
Postoperative recovery after ATAAD surgery.
Description
Patients will be assessed using the Postoperative recovery profile. Minimum score 19 points, maximum score 76 points, with 76 points being the best outcome.
Time Frame
3 months after surgery.
Title
Quality of life after ATAAD surgery.
Description
Patients will be assessed using the Satisfaction with life scale. Minimum score 0 points, maximum score 35 points, with 35 points being the best outcome.
Time Frame
3 months after surgery.
Title
Quality of life after ATAAD surgery.
Description
Patients will be assessed using the EuroQol 5 dimensions 5 levels (EQ-5D-5L). Minimum score 5 points, maximum score 25 points, with 5 points being the best outcome.
Time Frame
3 months after surgery.
Title
Number of ischemic lesions on magnetic resonance imaging (MRI) in relation to the use of retrograde cerebral perfusion.
Description
Number of ischemic lesions visualized using MRI analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
MRI will be performed before postoperative day 7. When not possible due to medical considerations, MRI may be performed up to 30 days after surgery.
Title
Size of ischemic lesions on magnetic resonance imaging (MRI) in relation to the use of retrograde cerebral perfusion.
Description
Size of ischemic lesions visualized using MRI analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
MRI will be performed before postoperative day 7. When not possible due to medical considerations, MRI may be performed up to 30 days after surgery.
Title
Levels of S100B analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Description
Concentration of S100B at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of NSE analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Description
Concentration of NSE at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of NFL analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Description
Concentration of NFL at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of GFAP analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Description
Concentration of GFAP at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of UCH-L1 analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Description
Concentration of UCH-L1 at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.
Title
Levels of TAU analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Description
Concentration of TAU at predefined time points analysed in subgroups with patients that have received retrograde cerebral perfusion and those who have not.
Time Frame
Preoperatively, 24 hours from start of surgery, postoperative day 4 and 3 months after surgery.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Verified acute type A aortic dissection. Patient accepted for surgical repair. Exclusion Criteria: New-onset neurological symptoms defined as focal neurological symptoms or altered state of consciousness at time of inclusion. History of stroke with permanent neurological deficiency. Previous cardiac surgery. Surgery performed with cross clamping of the aorta without open distal anastomosis or open inspection of the distal aorta. Presence of implants or devices not compatible with Magnetic Resonance Imaging.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Igor Zindovic, MD. PhD
Organizational Affiliation
Region Skåne, Skåne university hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skane University Hospital
City
Lund
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CARbon Dioxide Flooding to Reduce Postoperative Neurological Injury Following Surgery for Acute Type A Aortic Dissection

We'll reach out to this number within 24 hrs